Alnylam announces fda approval of supplemental new drug application for oxlumo® (lumasiran) in advanced primary hyperoxaluria type 1

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the u.s. food and drug administration (fda) approved a label expansion for oxlumo® (lumasiran), an rnai therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (ph1) to lower urinary oxalate (uox) and plasma oxalate (pox) levels in pediatric and adult patients. the approval is based on positive e
ALNY Ratings Summary
ALNY Quant Ranking